

Second edition 2017-02

## Cardiovascular implants — Endovascular devices —

# Part 1: **Endovascular prostheses**

Implants cardiovasculaires — Dispositifs endovasculaires — Partie 1: Prothèses endovasculaires



## ISO 25539-1:2017(E)

This is a preview of "ISO 25539-1:2017". Click here to purchase the full version from the ANSI store.



#### COPYRIGHT PROTECTED DOCUMENT

© ISO 2017, Published in Switzerland

All rights reserved. Unless otherwise specified, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office Ch. de Blandonnet 8 • CP 401 CH-1214 Vernier, Geneva, Switzerland Tel. +41 22 749 01 11 Fax +41 22 749 09 47 copyright@iso.org www.iso.org

| Coı    | Page  |   |          |  |  |
|--------|---|---|----------|--|--|
| Fore   | word  |   | v        |  |  |
| Intro  | oductio   | n   | vi       |  |  |
| 1      | Scop  | e   | 1        |  |  |
| 2      | -   |   |          |  |  |
| 3      |   | Normative references<br>Ferms and definitions   |          |  |  |
| 4      |   |   |          |  |  |
| •      | 4.1   | General requirements for endovascular system  4.1 Type of endovascular prosthesis                   |          |  |  |
|        | 4.2   | 4.2 Materials and construction for endovascular system  |          |  |  |
|        | 4.3   |   |          |  |  |
|        |   | <ul><li>4.4 Intended clinical use for endovascular system</li><li>4.5 Balloon designation</li></ul> |          |  |  |
| _      | 4.5   |   |          |  |  |
| 5<br>6 | Intended performance  |   |          |  |  |
|        | ,   | 6   |          |  |  |
|        | 6.1<br>6.2  | General Endovascular system   |          |  |  |
|        | 6.3   | Endovascular system Endovascular prosthesis   |          |  |  |
|        | 6.4   | Endovascular system and endovascular prosthesis   |          |  |  |
| 7      | Mate  | erials  |          |  |  |
| 8      | Design evaluation   |   |          |  |  |
| Ū      | 8.1   | General   |          |  |  |
|        | 8.2   | Sampling  |          |  |  |
|        | 8.3   | 3 Conditioning of test samples  |          |  |  |
|        | 8.4   | Reporting   |          |  |  |
|        | 8.5   | Bench and analytical tests  |          |  |  |
|        |   | 8.5.1 Endovascular system and delivery system   | 10<br>12 |  |  |
|        | 8.6   | Preclinical <i>in vivo</i> evaluation   |          |  |  |
|        | 0.0   | 8.6.1 Purpose   |          |  |  |
|        |   | 8.6.2 Specific aims   |          |  |  |
|        |   | 8.6.3 Protocol considerations   |          |  |  |
|        |   | 8.6.4 Data acquisition  |          |  |  |
|        | 8.7   | 8.6.5 Test report and additional information  |          |  |  |
|        | 0.7   | 8.7.1 Purpose   |          |  |  |
|        |   | 8.7.2 Specific aims   |          |  |  |
|        |   | 8.7.3 Protocol considerations   |          |  |  |
|        |   | 8.7.4 Data acquisition  |          |  |  |
|        |   | 8.7.5 Final report  | 26       |  |  |
| 9      | Post-   | -market surveillance  | 27       |  |  |
| 10     | Man   | ufacturing  | 27       |  |  |
| 11     | Steri   | 27  |          |  |  |
|        | 11.1  | Products supplied sterile   |          |  |  |
| 40     | 11.2  |   |          |  |  |
| 12     | Packaging 12.1 Protection from Jones in story and transport |   |          |  |  |
|        | 12.1  | Protection from damage in storage and transport   |          |  |  |
|        |   | 12.1.2 Unit container   |          |  |  |
|        |   | 12.1.3 Outer container  |          |  |  |
|        |   | 12.1.4 Shipping container   |          |  |  |

## ISO 25539-1:2017(E)

This is a preview of "ISO 25539-1:2017". Click here to purchase the full version from the ANSI store.

| 12.2                                     |                                  | Maintenance of sterility in transit   |    |
|--|----------------------------------|---|----|
| 12.2                                     | Labellin                         | g   | 28 |
|  |                                  | Container label   |    |
|  | 12.2.2                           | Record label  | 29 |
| 12.3                                     | Instruct                         | ions for use  | 29 |
|  | 12.3.1                           | General   | 29 |
|  | 12.3.2                           | Information and instructions for use for endovascular systems                 | 29 |
|  |                                  |   |    |
|  |                                  | Relationship between testing requirements and device attributes failure modes | 31 |
| and po                                   | otential                         |   |    |
| and po                                   | otential<br>ormative             | failure modes   | 45 |
| and po<br>Annex B (info<br>Annex C (info | otential<br>ormative<br>ormative | failure modes   | 45 |

## Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see <a href="https://www.iso.org/patents">www.iso.org/patents</a>).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation on the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT) see the following URL: www.iso.org/iso/foreword.html.

The committee responsible for this document is ISO/TC 150, *Implants for surgery*, Subcommittee SC 2, *Cardiovascular implants and extracorporeal systems*.

This second edition cancels and replaces the first edition (ISO 25539-1:2003), which has been technically revised.

It also incorporates the Amendment ISO 25539-1:2003/Amd1:2005.

A list of all the parts of ISO 25539 can be found on the ISO website.

## Introduction

This document was prepared to provide minimum requirements for endovascular prostheses. The normative requirements are provided in the main body. The rationale for the requirements for bench tests and analyses to assess device performance, guidance on the identification of appropriate testing to evaluate a specific device design and guidance for developing test methods are provided in informative annexes. Further clarification of terminology and a cross reference between the main body and these annexes are provided in additional informative annexes.

This document has been updated to reflect current knowledge regarding the testing and clinical use of endovascular prostheses, reflected in modifications to the requirements in the main body and in the guidance for developing test methods in <u>Annex D</u>. In addition, revisions have been made to improve consistency in nomenclature and reporting and to enhance the utility of this document.

This document introduces methodology to identify appropriate testing and analyses for specific endovascular prosthesis, designated as the device evaluation strategy (DES). The requirement regarding the DES is in the main body, with informative guidance for the preparation of a DES table included in Annex A. Annex A also provides guidance for developing a DES for device design modifications and changes in intended use.

The other significant modifications in the requirements include the addition of non-radial durability testing, with guidance on the selection of appropriate testing, and specific requirements for testing to evaluate patency-related characteristics. Guidance for the development of appropriate tests to meet these requirements is included in Annex D.

The guidance on the development of methods to address the requirement for evaluating fatigue and durability through computational analyses has been modified significantly to include recommendations regarding verification of the solution and validation of the computational model, as well as reporting. The guidance on the model development for simulated use has also been significantly revised to improve the clinical relevance of this testing.

New requirements also include the evaluation of leakage at a seal zone and dislodgement force of endovascular prosthesis from a balloon. Guidance for the development of appropriate tests to meet these requirements is included in  $\underbrace{\text{Annex D}}$ .

The requirement for evaluating the strength of the connection(s) between the graft material and a discrete fixation system(s) has been clarified with respect to the applicability of this requirement, that is, this requirement is only applicable for prostheses with a fixation system that is discrete from any stent(s) intended to provide structural support within the prosthesis [e.g. suprarenal stent that is not continuous with the stent(s) in the prosthesis body].

The specific requirements to evaluate pushability, flexibility, torquability, trackability and deployment accuracy of an endovascular system have been removed and incorporated within the simulated use evaluation requirement to better reflect how these attributes are evaluated. Similarly, the requirement to evaluate tubing tensile strength has been removed and incorporated within the evaluation of tensile bond strength.

The requirement to evaluate stent-free surface area has been removed as this attribute is not relevant for endovascular prostheses, which includes covered stents.

In addition to modifications to specific design evaluation requirements, guidance has been provided regarding the assessment of the acceptability of test results. When the requirement is to quantitatively appraise or analyse a parameter, test results generally may be compared to a quantitative value (i.e. acceptance criteria). For characterization tests, it is appropriate to provide an explanation of the relevance of the results. Additionally, some testing may include comparison to test data or existing data from a previously evaluated device.

For design evaluation, requirements regarding sampling, conditioning of test samples and reporting have been incorporated in the main body. Guidance on these elements of testing and documentation were previously included in  $\underbrace{\text{Annex }D}$ .

The revisions to the titles of the annexes to this document are as follows.

| Annex | ISO 25539-1:2003+A1:2005  | ISO 25539-1:2017  |
|-------|---|---|
| A     | Attributes of endovascular devices —<br>Technical and clinical considerations | Relationship between testing requirements and device attributes and potential failure modes |
| В     | Bench and analytical tests  | Description of device and clinical effects of failure                                       |
| С     | Definitions of reportable clinical events                                     | Bench and analytical tests  |
| D     | Test methods  | Test methods  |
| Е     | Sample equations as a supplement to the radial fatigue and durability test    | There is no Annex E as this information was incorporated in Annex D                         |

It is recognised by this ISO committee that many endovascular systems have been shown to be safe and effective in clinical use. This update is not intended to require additional evaluation of these devices to remain in compliance with this document as the testing would not provide useful information regarding the expected clinical performance of the device. Manufacturers may rely on historical data gathered under the guidance of the previous version of this document. Similarly, for device modifications or changes in intended clinical use, this update is not intended to require additional evaluation of any aspects of the device that are not expected to change clinical performance.